The epidemiology of nonalcoholic fatty liver disease in adults - PubMed (original) (raw)
Review
The epidemiology of nonalcoholic fatty liver disease in adults
Jeanne M Clark. J Clin Gastroenterol. 2006 Mar.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease that has been shown to progress to cirrhosis and hepatocellular carcinoma. This article reviews the prevalence of NAFLD and the factors associated this disorder, and with the more advanced stages of NAFLD, including nonalcoholic steatohepatitis (NASH) and fibrosis. In the general population, the estimated prevalence ranges from 3% to 24%, with most estimates in the 6% to 14% range. NAFLD is extremely common among patients undergoing bariatric surgery, ranging from 84% to 96%. In these patients, 25% to 55% have NASH, 34% to 47% have fibrosis, and 2% to 12% have bridging fibrosis or cirrhosis. NAFLD appears to be most strongly associated with obesity, and insulin resistance states including diabetes and with other features of the metabolic syndrome, such as high triglycerides and low HDL. It appears to be more common in men, and it increases with increasing age and after menopause. Some data suggest that Mexican Americans are more likely to have NAFLD and blacks are less likely compared with non-Hispanic whites. More advanced stages of NAFLD are associated with older age, higher body mass index, diabetes, hypertension, high triglycerides, and/or insulin resistance. An AST/ALT ratio greater >1 may also indicate more severe disease. Although hepatocellular carcinoma can occur in the setting of NAFLD, the risk factors for hepatocellular carcinoma in the setting of NAFLD have not been established. More prospective studies are needed to determine the true risk factors for the development and progression of NAFLD to help identify patients at highest risk who might benefit from treatment trials.
Similar articles
- Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients.
Ong JP, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines HD, Goodman Z, Younossi ZM. Ong JP, et al. Obes Surg. 2005 Mar;15(3):310-5. doi: 10.1381/0960892053576820. Obes Surg. 2005. PMID: 15826462 - Nonalcoholic fatty liver disease in severely obese subjects.
Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP. Gholam PM, et al. Am J Gastroenterol. 2007 Feb;102(2):399-408. doi: 10.1111/j.1572-0241.2006.01041.x. Am J Gastroenterol. 2007. PMID: 17311652 - What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?
Fan JG, Saibara T, Chitturi S, Kim BI, Sung JJ, Chutaputti A; Asia-Pacific Working Party for NAFLD. Fan JG, et al. J Gastroenterol Hepatol. 2007 Jun;22(6):794-800. doi: 10.1111/j.1440-1746.2007.04952.x. Epub 2007 May 13. J Gastroenterol Hepatol. 2007. PMID: 17498218 - [Non-alcoholic fatty liver disease--new view].
Raszeja-Wyszomirska J, Lawniczak M, Marlicz W, Miezyńska-Kurtycz J, Milkiewicz P. Raszeja-Wyszomirska J, et al. Pol Merkur Lekarski. 2008 Jun;24(144):568-71. Pol Merkur Lekarski. 2008. PMID: 18702346 Review. Polish. - The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease.
McCullough AJ. McCullough AJ. Clin Liver Dis. 2004 Aug;8(3):521-33, viii. doi: 10.1016/j.cld.2004.04.004. Clin Liver Dis. 2004. PMID: 15331061 Review.
Cited by
- Effect of silymarin on liver size and nonalcoholic fatty liver disease in morbidly obese patients: A randomized double-blind clinical trial.
Atarodi H, Pazouki A, Gholizadeh B, Karami R, Kabir A, Sadri G, Kassir R, Kermansaravi M. Atarodi H, et al. J Res Med Sci. 2022 Oct 31;27:76. doi: 10.4103/jrms.jrms_683_21. eCollection 2022. J Res Med Sci. 2022. PMID: 36438071 Free PMC article. - PSA controls hepatic lipid metabolism by regulating the NRF2 signaling pathway.
Huang B, Xiong X, Zhang L, Liu X, Wang Y, Gong X, Sang Q, Lu Y, Qu H, Zheng H, Zheng Y. Huang B, et al. J Mol Cell Biol. 2021 Oct 21;13(7):527-539. doi: 10.1093/jmcb/mjab033. J Mol Cell Biol. 2021. PMID: 34048566 Free PMC article. - Nonalcoholic Fatty Liver Disease Relationship with Metabolic Syndrome in Class III Obesity Individuals.
Cordeiro A, Pereira SE, Saboya CJ, Ramalho A. Cordeiro A, et al. Biomed Res Int. 2015;2015:839253. doi: 10.1155/2015/839253. Epub 2015 May 18. Biomed Res Int. 2015. PMID: 26120587 Free PMC article. - Long-term effects of one-anastomosis gastric bypass on liver histopathology in NAFLD cases: a prospective study.
Salman MA, Salman AA, Omar HSE, Abdelsalam A, Mostafa MS, Tourky M, Sultan AAEA, Elshafey MH, Abdelaty WR, Salem A, Khaliel OO, Elshafey HE, Atallah M, Shaaban HE, Yousef M, Nafea MA. Salman MA, et al. Surg Endosc. 2021 Apr;35(4):1889-1894. doi: 10.1007/s00464-020-07725-y. Epub 2020 Jun 16. Surg Endosc. 2021. PMID: 32556752 - Recent Advances in Understanding of NASH: MicroRNAs as Both Biochemical Markers and Players.
Vincent R, Sanyal A. Vincent R, et al. Curr Pathobiol Rep. 2014 Sep 1;2(3):109-115. doi: 10.1007/s40139-014-0049-8. Curr Pathobiol Rep. 2014. PMID: 25574453 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources